Hematocrit Test Devices Market Report, Global, 2024

The hematocrit test devices market size has grown strongly in recent years. It will grow from $4.35 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth observed during the historic period can be attributed to several factors, including increased awareness regarding anemia and deficiencies in iron and vitamins, a rise in the incidence of chronic illnesses, increased government funding, and population growth.

The hematocrit test devices market size is expected to see strong growth in the next few years. It will grow to $5.98 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing prevalence of anemia, growing cases of blood disorders, a rise in the geriatric population, heightened focus on health and fitness, and a widening need for cardiovascular diagnostic equipment. Major trends expected during this period include the introduction of cutting-edge solutions, advancements in technology within the medical science field, creation of new efficient and innovative products, technical developments in hematocrit testing, and overall advancements in the healthcare sector.

The increasing instances of blood disorders are anticipated to drive the expansion of the hematocrit test devices market in the coming years. Blood disorders encompass conditions affecting the various components of human blood, such as red blood cells, white blood cells, platelets, and plasma. These disorders are becoming more prevalent due to a combination of factors including genetic factors, environmental pollution, and changes in lifestyle. Hematocrit test devices play a vital role in measuring the volume percentage of red blood cells in whole blood, offering essential insights into the patient's hematological well-being. For example, a report published by the American Cancer Society in January 2024 projects approximately 62,770 new cases of leukemia in the United States for 2024, leading to an estimated 23,670 deaths. Among these cases, around 20,800 new instances of acute myeloid leukemia (AML) are expected, predominantly affecting adults, with approximately 11,220 deaths attributed to AML, primarily occurring in adult patients. Thus, the rising occurrences of blood disorders are stimulating the growth of the hematocrit test devices market.

Leading companies in the hematocrit test device market are innovating their product offerings, such as complete blood count (CBC) hematology analyzers, to deliver both quantitative and qualitative information about blood cells. A complete blood count (CBC) hematology analyzer is an automated instrument utilized to measure and analyze various components of blood, including red blood cells (RBCs), white blood cells (WBCs), and platelets. For instance, in March 2022, Mindray Medical International Limited, a China-based medical device company, introduced the BC-700 hematology analyzer series. This series encompasses both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests, catering to medium-volume laboratories with advanced diagnostic technologies akin to premium products. The BC-700 Series, including models such as BC-720, BC-760, and BC-780, is a more compact iteration of the high-end BC-6000 Series, featuring Mindray's SF Cube 3D analysis technology. Leveraging fluorescence and bi-angular laser scatter signals, the SF Cube technology enables three-dimensional analysis of target cells.

In June 2023, Mars Incorporated, a US-based packaged food products manufacturer, acquired Heska Corporation for $1.3 billion. With this acquisition, Heska now operates under Mars Petcare's Science & Diagnostics division, expanding its reach in diagnostics and technology. The integration facilitates accelerated research and development efforts while enhancing global access to pet healthcare solutions. Heska Corporation specializes in manufacturing hematocrit test devices.

Major companies operating in the hematocrit test devices market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton, Dickinson and Company (BD), Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMérieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, Heska Corporation, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory Lp, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, Mikroscan Technologies Inc.

North America was the largest region in the hematocrit test devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematocrit test devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematocrit test devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hematocrit test devices are medical instruments utilized to measure the percentage of red blood cells (RBCs) in a person's total blood volume. These devices serve various purposes, including monitoring chronic conditions, preoperative assessments, detecting blood doping, screening blood donors, managing emergencies, and conducting research and clinical trials.

The primary types of hematocrit test devices include hematocrit test meters, hematocrit test analyzers, and reagents and consumables. A hematocrit (HCT) test meter is a point-of-care device employed to measure the percentage of red blood cells in whole blood. It finds applications in conditions such as anemia, polycythemia vera, congenital heart diseases, among others, and is utilized by various end-users, including hospitals and ambulatory surgical centers, clinics, diagnostic and pathology labs, among others.

The hematocrit test devices market research report is one of a series of new reports that provides hematocrit test devices market statistics, including hematocrit test devices industry global market size, regional shares, competitors with a hematocrit test devices market share, detailed hematocrit test devices market segments, market trends and opportunities, and any further data you may need to thrive in the hematocrit test devices industry. This hematocrit test devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hematocrit test devices market consists of sales of hematocrit centrifuges, test strips, capillary transfer tubes, and adapter kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.